Michael A. Carducci

Papers

Total Citations

H-Index

About

Michael A. Carducci is a leading oncologist and researcher whose work has profoundly shaped the treatment of advanced prostate cancer, particularly through the lens of oligometastatic disease. His primary research focuses on the biology of castration-resistant prostate cancer (CRPC) and the development of novel therapeutic strategies, including targeted therapies and immunotherapies. Carducci is perhaps best known for his pioneering contributions to the clinical application of stereotactic ablative radiation therapy (SABR) for oligometastatic prostate cancer, a paradigm-shifting approach that challenges traditional views on metastatic disease. His landmark 2016 study on SABR for oligometastatic prostate cancer, while modest in citation count, has been instrumental in launching a new wave of clinical trials and redefining treatment guidelines. Beyond this, Carducci has been a key figure in the development of drugs like abiraterone and enzalutamide, and his work has garnered thousands of citations across his broader portfolio. A dedicated mentor and former director of the Prostate Cancer Program at the Sidney Kimmel Comprehensive Cancer Center, Carducci’s legacy lies in bridging laboratory discoveries with life-extending therapies for patients.